In tumors with increased expression of CD44, the using of HA‐based nanocarriers was reported to have the benefits in the enhancement of drug delivery, the increase therapeutic efficacy with low cytotoxicity, the inhibition of tumor growth, as well as the high potential for targeted chemotherapy.149. This evidence concerns the gene CD44 and neoplasm.